Evidence map›Paper›PMID 17331479›Full record

ArticleBrain research2007

Glutamatergic or GABAergic neuron-specific, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter.

Morten Rasmussen, Lingxin Kong, Guo-rong Zhang, Meng Liu, Xiaodan Wang, Gabor Szabo, Norman P Curthoys, Alfred I Geller

Abstract read
In one paragraph

Article in Brain research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Gene Therapy Tools for Brain Diseases.Frontiers in pharmacology · 2019
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Gene therapy for Parkinson's disease.Parkinson's disease · 2012
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Morten RasmussenDepartment of Neurology, Research Building 3, West Roxbury VA Hospital/Harvard Medical School, 1400 VFW Parkway, West Roxbury, MA 02132, USA.
Lingxin Kong
Guo-rong Zhang
Meng Liu
Xiaodan Wang
Gabor Szabo
Norman P Curthoys
Alfred I Geller
Colorado State University · USHungarian Academy of Sciences · HU

Funding

Promoters for Long-term Expression from HSV-1 VectorsR01NS045855 · NINDS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GELLER, ALFRED I. · 2003 to 2011
$2.0M
GENE THERAPY FOR AGING DISORDERSR01AG016777 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GELLER, ALFRED I. · 2000 to 2004
$1.4M
High-titer helper virus-free HSV-1 vectorsR01AG021193 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GELLER, ALFRED I. · 2003 to 2007
$1.3M
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 VectorsR01NS057558 · NINDS · HARVARD MEDICAL SCHOOL · PI GELLER, ALFRED I. · 2007 to 2011
$1.3M
Enhanced HSV-1 Vector Particles for Neural Gene TherapyR01NS043107 · NINDS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GELLER, ALFRED I. · 2001 to 2004
$1.1M
NIA NIH HHS AG021193NIA NIH HHS AG16777NIA NIH HHS R01 AG016777NIA NIH HHS R01 AG021193NINDS NIH HHS NS043107NINDS NIH HHS NS045855NINDS NIH HHS R01 NS043107NINDS NIH HHS R01 NS045855NINDS NIH HHS R01 NS057558
6 · The paper itself

Abstract

Many potential uses of direct gene transfer into neurons require restricting expression to one of the two major types of forebrain neurons, glutamatergic or GABAergic neurons. Thus, it is desirable to develop virus vectors that contain either a glutamatergic or GABAergic neuron-specific promoter. The brain/kidney phosphate-activated glutaminase (PAG), the product of the GLS1 gene, produces the majority of the glutamate for release as neurotransmitter, and is a marker for glutamatergic neurons. A PAG promoter was partially characterized using a cultured kidney cell line. The three vesicular glutamate transporters (VGLUTs) are expressed in distinct populations of neurons, and VGLUT1 is the predominant VGLUT in the neocortex, hippocampus, and cerebellar cortex. Glutamic acid decarboxylase (GAD) produces GABA; the two molecular forms of the enzyme, GAD65 and GAD67, are expressed in distinct, but largely overlapping, groups of neurons, and GAD67 is the predominant form in the neocortex. In transgenic mice, an approximately 9 kb fragment of the GAD67 promoter supports expression in most classes of GABAergic neurons. Here, we constructed plasmid (amplicon) Herpes Simplex Virus (HSV-1) vectors that placed the Lac Z gene under the regulation of putative PAG, VGLUT1, or GAD67 promoters. Helper virus-free vector stocks were delivered into postrhinal cortex, and the rats were sacrificed 4 days or 2 months later. The PAG or VGLUT1 promoters supported approximately 90% glutamatergic neuron-specific expression. The GAD67 promoter supported approximately 90% GABAergic neuron-specific expression. Long-term expression was observed using each promoter. Principles for obtaining long-term expression from HSV-1 vectors, based on these and other results, are discussed. Long-term glutamatergic or GABAergic neuron-specific expression may benefit specific experiments on learning or specific gene therapy approaches. Of note, promoter analyses might identify regulatory elements that determine a glutamatergic or GABAergic neuron.

Indexed as

AnimalsCell CountCell Line, TransformedCricetinaegamma-Aminobutyric AcidGene Expression RegulationGenetic VectorsGlutamate DecarboxylaseGlutamic AcidGlutaminaseHerpesvirus 1, HumanMaleNeocortexNeuronsPromoter Regions, GeneticRatsgamma-Aminobutyric AcidGlutamate DecarboxylaseGlutamic AcidGlutaminaseVesicular Glutamate Transport Protein 1

Identifiers

PMID17331479
PMCPMC2694742
OpenAlexW2084408327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.